Expression Defect Size among Unclassified MLH1 Variants Determines Pathogenicity in Lynch Syndrome Diagnosis
Authors:
- 30 April 2013
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 19 (9) , 2432-2441
Abstract
Purpose: Lynch syndrome is caused by a germline mutation in a mismatch repair gene, most commonly the MLH1 gene. However, one third of the identified alterations are missense variants with unclear clinical significance. The functionality of these variants can be tested in the laboratory, but the results cannot be used for clinical diagnosis. We therefore aimed to establish a laboratory test that can be applied clinically. Experimental Design: We assessed the expression, stability, and mismatch repair activity of 38 MLH1 missense variants and determined the pathogenicity status of recurrent variants using clinical data. Results: Four recurrent variants were classified as neutral (K618A, H718Y, E578G, V716M) and three as pathogenic (A681T, L622H, P654L). All seven variants were proficient in mismatch repair but showed defects in expression. Quantitative PCR, pulse-chase, and thermal stability experiments confirmed decreases in protein stability, which were stronger in the pathogenic variants. The minimal cellular MLH1 concentration for mismatch repair was determined, which corroborated that strongly destabilized variants can cause repair deficiency. Loss of MLH1 tumor immunostaining is consistently reported in carriers of the pathogenic variants, showing the impact of this protein instability on these tumors. Conclusions: Expression defects are frequent among MLH1 missense variants, but only severe defects cause Lynch syndrome. The data obtained here enabled us to establish a threshold for distinguishing tolerable (clinically neutral) from pathogenic expression defects. This threshold allows the translation of laboratory results for uncertain MLH1 variants into pathogenicity statements for diagnosis, thereby improving the targeting of cancer prevention measures in affected families. Clin Cancer Res; 19(9); 2432–41. ©2013 AACR.Keywords
All Related Versions
This publication has 48 references indexed in Scilit:
- DNA Repair: From Genome Maintenance to Biomarker and Therapeutic TargetClinical Cancer Research, 2011
- Evidence for classification of c.1852_1853AA>GC in MLH1 as a neutral variant for Lynch syndromeBMC Medical Genetics, 2011
- Identification of Lynch syndrome mutations in the MLH1-PMS2 interface that disturb dimerization and mismatch repairHuman Mutation, 2010
- Hereditary and Familial Colon CancerGastroenterology, 2010
- Microsatellite instability in the peripheral blood leukocytes of HNPCC patientsHuman Mutation, 2010
- Assessing pathogenicity: overview of results from the IARC Unclassified Genetic Variants Working GroupHuman Mutation, 2008
- Assessment of functional effects of unclassified genetic variantsHuman Mutation, 2008
- Determination of Cancer Risk Associated with Germ Line BRCA1 Missense Variants by Functional AnalysisCancer Research, 2007
- Mutations in the MutSα interaction interface of MLH1 can abolish DNA mismatch repairNucleic Acids Research, 2006
- Structure and function of the N‐terminal 40 kDa fragment of human PMS2: a monomeric GHL ATPaseThe EMBO Journal, 2001